Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Avacopan | CCX-168 | Approved | Chemocentryx | Tavneos, Vynpenta, タブネオスカプセル | EU | Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Vifor Fresenius Medical Care Renal Pharma France Vifor Sa | 2021-09-27 | Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TJ-210001 | MOR-210; MOR044254; TJ 210; TJ210001; WBP-2191; TJ-210001; TJ-210; MOR-044254 | Phase 1 Clinical | Morphosys | Solid tumours | Details |
AON-D-21 | AON-D-21 | Details | |||
MP-435 | MP-435 | Mitsubishi Tanabe Pharma Corp | Details | ||
Avdoralimab | NNC-0215-0384; IPH-5401; Anti-C5aR-215; NN-8210 | Phase 2 Clinical | Novo Nordisk A/S | Solid tumours; Arthritis, Rheumatoid; Neoplasms; Coronavirus Infections; Pemphigoid, Bullous; Inflammation | Details |
This web search service is supported by Google Inc.